ArticleAmerican journal of translational research2013
Hepatic fatty acid and cholesterol metabolism in nephrotic syndrome.
Article in American journal of translational research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Associations between lipid metabolism and Henoch-Schönlein purpura nephritis in children: a systematic review and meta-analysis.Italian journal of pediatrics · 2026Pooled it
- Voclosporin ameliorates proteinuria in a model of non-inflammatory glomerular disease.BMC nephrology · 2026Article
- Identification of key genes in membranous nephropathy and non-alcoholic fatty liver disease by bioinformatics and machine learning.Frontiers in immunology · 2025Article
- Risk factors of disease activity and renal damage in patients with systemic lupus erythematosus.International urology and nephrology · 2024Article
- Whole-exome sequencing identifies novel protein-altering variants associated with serum apolipoprotein and lipid concentrations.Genome medicine · 2022Article
- Signaling pathways of chronic kidney diseases, implications for therapeutics.Signal transduction and targeted therapy · 2022Review
- The causal effects of serum lipids and apolipoproteins on kidney function: multivariable and bidirectional Mendelian-randomization analyses.International journal of epidemiology · 2021Article
- Hepatic transcriptome analysis reveals altered lipid metabolism and consequent health indices in chicken supplemented with dietary Bifidobacterium bifidum and mannan-oligosaccharides.Scientific reports · 2021Article
- Live ProbioticFrontiers in microbiology · 2017Article
- Effects of Bacillus licheniformis on the growth performance and expression of lipid metabolism-related genes in broiler chickens challenged with Clostridium perfringens-induced necrotic enteritis.Lipids in health and disease · 2016Article
- A mutation in Ampd2 is associated with nephrotic syndrome and hypercholesterolemia in mice.Lipids in health and disease · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Heavy proteinuria (nephrotic syndrome) is associated with hypercholesterolemia, hypertriglyceridemia and a high risk of atherosclerosis. Hypertriglyceridemia in nephrotic syndrome (NS) is partly due to increased TG and TG-rich lipoprotein production. However, data on the effect of NS on fatty acid production and catabolic machinery are limited. NS was induced in male Sprague Dawley rats by IP injection of puromycin aminonucleoside. Six weeks after the second injection the animals were euthanized, liver was harvested and processed. The NS group exhibited heavy proteinuria, hypercholesterolemia, hypertriglyceridemia, activation of SREBP-1 and LXR α/β, up-regulation of FAS, ACC and HMG CoA reductase. In contrast hepatic tissue ChREBP activity was reduced in NS excluding its role in upregulation of FA synthetic pathway. Despite increased expression and nuclear translocation of PPARα, expression of ACO and abundance of CPT and L-FABP, were decreased in the liver of nephrotic animals. Therefore, NS results in upregulation of FA production machinery. Increased hepatic fatty acid production capacity in NS is compounded by reduced FA catabolism, events that contribute to the associated hypertiglyceridemia.
Indexed as
Identifiers
23573368PMC3612519W1605105964What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.